Osteogenic ability of rat bone marrow concentrate is at least as efficacious as mesenchymal stem cells in vitro
Yusuke Kohno
Department of Orthopaedic Surgery, Stanford University, Stanford, California
Search for more papers by this authorTzuhua Lin
Department of Orthopaedic Surgery, Stanford University, Stanford, California
Search for more papers by this authorJukka Pajarinen
Department of Orthopaedic Surgery, Stanford University, Stanford, California
Search for more papers by this authorMonica Romero-Lopez
Department of Orthopaedic Surgery, Stanford University, Stanford, California
Search for more papers by this authorMasahiro Maruyama
Department of Orthopaedic Surgery, Stanford University, Stanford, California
Search for more papers by this authorJhih-Fong Huang
Department of Orthopaedic Surgery, Stanford University, Stanford, California
Search for more papers by this authorKarthik Nathan
Department of Orthopaedic Surgery, Stanford University, Stanford, California
Search for more papers by this authorZhenyu Yao
Department of Orthopaedic Surgery, Stanford University, Stanford, California
Search for more papers by this authorCorresponding Author
Stuart B. Goodman
Department of Orthopaedic Surgery, Stanford University, Stanford, California
Department of Bioengineering, Stanford University, Stanford, California
Correspondence to: S. B. Goodman; e-mail: [email protected]Search for more papers by this authorYusuke Kohno
Department of Orthopaedic Surgery, Stanford University, Stanford, California
Search for more papers by this authorTzuhua Lin
Department of Orthopaedic Surgery, Stanford University, Stanford, California
Search for more papers by this authorJukka Pajarinen
Department of Orthopaedic Surgery, Stanford University, Stanford, California
Search for more papers by this authorMonica Romero-Lopez
Department of Orthopaedic Surgery, Stanford University, Stanford, California
Search for more papers by this authorMasahiro Maruyama
Department of Orthopaedic Surgery, Stanford University, Stanford, California
Search for more papers by this authorJhih-Fong Huang
Department of Orthopaedic Surgery, Stanford University, Stanford, California
Search for more papers by this authorKarthik Nathan
Department of Orthopaedic Surgery, Stanford University, Stanford, California
Search for more papers by this authorZhenyu Yao
Department of Orthopaedic Surgery, Stanford University, Stanford, California
Search for more papers by this authorCorresponding Author
Stuart B. Goodman
Department of Orthopaedic Surgery, Stanford University, Stanford, California
Department of Bioengineering, Stanford University, Stanford, California
Correspondence to: S. B. Goodman; e-mail: [email protected]Search for more papers by this authorAbstract
Cell therapy using bone marrow concentrate (BMC) or purified and expanded mesenchymal stem cells (MSCs) has been shown to have a promising osteogenic capacity. However, few studies have directly compared their relative osteogenic ability. The aim of this study was to compare the osteogenic ability of BMC isolated by density gradient centrifugation with bone marrow-derived MSCs in vitro using the cells of 3-month-old Sprague–Dawley rats. The isolated cells were seeded onto 24-well plates (1 × 105 cells/well) and cultured in control growth media, osteogenic media with dexamethasone, or media without dexamethasone (which simulated the in vivo tissue environment). Alkaline phosphatase activity at week 2, osteocalcin using quantitative real-time polymerase chain reaction at week 4, and Alizarin red staining at week 4 were evaluated. In the osteogenic media with dexamethasone, BMC showed equivalent (osteocalcin) or even greater (Alizarin red staining) osteogenic ability compared to MSCs, suggesting that cross-talk among various cells in the BMC leads to greater osteogenesis. Furthermore, in the osteogenic media without dexamethasone, BMC showed equivalent (osteocalcin) or a trend for greater (Alizarin red staining) bone formation than MSCs alone. Our results suggest that BMC has at least comparable bone regeneration potential to MSCs. © 2019 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater 107B:2500–2506, 2019
REFERENCES
- 1Caplan AI, Mason C, Reeve B. The 3Rs of cell therapy. Stem Cells Transl Med 2017; 6: 17–21.
- 2Yorukoglu AC, Kiter AE, Akkaya S, Satiroglu-Tufan NL, Tufan AC. A concise review on the use of mesenchymal stem cells in cell sheet-based tissue engineering with special emphasis on bone tissue regeneration. Stem Cells Int 2017; 2017: 2374161.
- 3Smith JO, Aarvold A, Tayton ER, Dunlop DG, Oreffo RO. Skeletal tissue regeneration: Current approaches, challenges, and novel reconstructive strategies for an aging population. Tissue Eng Part B Rev 2011; 17: 307–320.
- 4Marler JJ, Upton J, Langer R, Vacanti JP. Transplantation of cells in matrices for tissue regeneration. Adv Drug Deliv Rev 1998; 33: 165–182.
- 5Goodman SB. Cell-based therapies for regenerating bone. Minerva Ortop Traumatol 2013; 64: 107–113.
- 6Dawson JI, Smith JO, Aarvold A, Ridgway JN, Curran SJ, Dunlop DG, Oreffo RO. Enhancing the osteogenic efficacy of human bone marrow aspirate: Concentrating osteoprogenitors using wave-assisted filtration. Cytotherapy 2013; 15: 242–252.
- 7Jäger M, Hernigou P, Zilkens C, Herten M, Li X, Fischer J, Krauspe R. Cell therapy in bone healing disorders. Orthop Rev (Pavia) 2010; 2: e20.
- 8Goodman SB, Hwang KL. Treatment of secondary osteonecrosis of the knee with local debridement and osteoprogenitor cell grafting. J Arthroplast 2015; 30: 1892–1896.
- 9Goodman SB. The biological basis for concentrated iliac crest aspirate to enhance core decompression in the treatment of osteonecrosis. Int Orthop 2018; 42: 1705–1709.
- 10Samsonraj RM, Raghunath M, Nurcombe V, Hui JH, van Wijnen AJ, Cool SM. Concise review: Multifaceted characterization of human mesenchymal stem cells for use in regenerative medicine. Stem Cells Transl Med 2017; 6: 2173–2185.
- 11Caplan AI. Review: Mesenchymal stem cells: Cell-based reconstructive therapy in orthopedics. Tissue Eng 2005; 11: 1198–1211.
- 12Bruder SP, Kraus KH, Goldberg VM, Kadiyala S. The effect of implants loaded with autologous mesenchymal stem cells on the healing of canine segmental bone defects. J Bone Joint Surg Am 1998; 80: 985–996.
- 13Quarto R, Mastrogiacomo M, Cancedda R, Kutepov SM, Mukhachev V, Lavroukov A, Kon E, Marcacci M. Repair of large bone defects with the use of autologous bone marrow stromal cells. N Engl J Med 2001; 344: 385–386.
- 14Hernigou P, Trousselier M, Roubineau F, Bouthors C, Chevallier N, Rouard H, Flouzat-Lachaniette CH. Stem cell therapy for the treatment of hip osteonecrosis: A 30-year review of progress. Clin Orthop Surg 2016; 8(1): 1–8.
- 15Aoyama T, Goto K, Kakinoki R, Ikeguchi R, Ueda M, Kasai Y, Maekawa T, Tada H, Teramukai S, Nakamura T, Toguchida J. An exploratory clinical trial for idiopathic osteonecrosis of femoral head by cultured autologous multipotent mesenchymal stromal cells augmented with vascularized bone grafts. Tissue Eng Part B Rev 2014; 20: 233–242.
- 16Trainor N, Pietak A, Smith T. Rethinking clinical delivery of adult stem cell therapies. Nat Biotechnol 2014; 32: 729–735.
- 17Seebach C, Henrich D, Schaible A, Relja B, Jugold M, Bönig H, Marzi I. Cell-based therapy by implanted human bone marrow-derived mononuclear cells improved bone healing of large bone defects in rats. Tissue Eng Part A 2015; 21: 1565–1578.
- 18Wang Y, Han ZB, Song YP, Han ZC. Safety of mesenchymal stem cells for clinical application. Stem Cells Int 2012; 2012: 652034.
- 19Hernigou P, Poignard A, Beaujean F, Rouard H. Percutaneous autologous bone-marrow grafting for nonunions. Influence of the number and concentration of progenitor cells. J Bone Joint Surg Am 2005; 87: 1430–1437.
- 20Hernigou P, Poignard A, Manicom O, Mathieu G, Rouard H. The use of percutaneous autologous bone marrow transplantation in nonunion and avascular necrosis of bone. J Bone Joint Surg Br 2005; 87: 896–902.
- 21Jäger M, Jelinek EM, Wess KM, Scharfstädt A, Jacobson M, Kevy SV, Krauspe R. Bone marrow concentrate: A novel strategy for bone defect treatment. Curr Stem Cell Res Ther 2009; 4: 34–43.
- 22Hernigou P, Beaujean F. Treatment of osteonecrosis with autologous bone marrow grafting. Clin Orthop Relat Res 2002; 405: 14–23.
- 23Sugaya H, Yoshioka T, Kato T, Taniguchi Y, Kumagai H, Hyodo K, Ohneda O, Yamazaki M, Mishima H. Comparative analysis of cellular and growth factor composition in bone marrow aspirate concentrate and platelet-rich plasma. Bone Marrow Res 2018; 2018: 1549826.
- 24Pajarinen J, Lin T, Gibon E, Kohno Y, Maruyama M, Nathan K, Lu L, Yao Z, Goodman SB. Mesenchymal stem cell-macrophage crosstalk and bone healing. Biomaterials 2018. https://doi.org/10.1016/j.biomaterials.2017.12.025.
- 25Loi F, Córdova LA, Zhang R, Pajarinen J, Lin TH, Goodman SB, Yao Z. The effects of immunomodulation by macrophage subsets on osteogenesis in vitro. Stem Cell Res Ther 2016; 7: 15.
- 26Mountziaris PM, Spicer PP, Kasper FK, Mikos AG. Harnessing and modulating inflammation in strategies for bone regeneration. Tissue Eng Part B Rev 2011; 17: 393–402.
- 27Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop Dj, Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8: 315–317.
- 28Tokalov SV, Gruener S, Schindler S, Iagunov AS, Baumann M, Abolmaali ND. A number of bone marrow mesenchymal stem cells but neither phenotype nor differentiation capacities changes with age of rats. Mol Cells 2007; 24: 255–260.
- 29Sacchetti B, Funari A, Michienzi S, Di Cesare S, Piersanti S, Saggio I, Tagliafico E, Ferrari S, Robey PG, Riminucci M, Bianco P. Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell 2007; 131: 324–336.
- 30Lin TH, Sato T, Barcay KR, Waters H, Loi F, Zhang R, Pajarinen J, Egashira K, Yao Z, Goodman SB. NF-κB decoy oligodeoxynucleotide enhanced osteogenesis in mesenchymal stem cells exposed to polyethylene particle. Tissue Eng Part A 2015; 21: 875–883.
- 31Schneider CA, Rasband WS, Eliceiri KW. NIH image to ImageJ: 25 years of image analysis. Nat Methods 2012; 9: 671–675.
- 32Huang W, Yang S, Shao J, Li YP. Signaling and transcriptional regulation in osteoblast commitment and differentiation. Front Biosci 2007; 12: 3068–3092.
- 33Ducy P, Karsenty G. Two distinct osteoblast-specific cis-acting elements control expression of a mouse osteocalcin gene. Mol Cell Biol 1995; 15: 1858–1869.
- 34Puchtler H, Meloan SN, Terry MS. On the history and mechanism of alizarin and alizarin red S stains for calcium. J Histochem Cytochem 1969; 17: 110–124.
- 35Loi F, Córdova LA, Pajarinen J, Lin TH, Yao Z, Goodman SB. Inflammation, fracture and bone repair. Bone 2016; 86: 119–130.
- 36Jaiswal N, Haynesworth SE, Caplan AI, Bruder SP. Osteogenic differentiation of purified, culture-expanded human mesenchymal stem cells in vitro. J Cell Biochem 1997; 64: 295–312.
10.1002/(SICI)1097-4644(199702)64:2<295::AID-JCB12>3.0.CO;2-I CAS PubMed Web of Science® Google Scholar
